Treating Brain Metastases in the Changing World of Oncology: Matthew Ewend, MD Kay and Van Weatherspoon Professor Chair, Department of Neurosurgery

Transcription

1 Treating Brain Metastases in the Changing World of Oncology: Matthew Ewend, MD Kay and Van Weatherspoon Professor Chair, Department of Neurosurgery

2 Disclosures Consultant: None Stock Holdings: None Paid Speaking Arrangements: None Research Support: Eisai Gliadel for Brain Metastases Off Label Gliadel BCNU wafers Would everyone check to see they have their attorney? I seem to have ended up with two

3 CNS Metastasis by Primary Site Ryken T et al. Textbook of Neurooncology, 2005 Total CNS mets per year ~98, ,000.

4 With rare excepfons, treatment of brain metastases is palliafve Survival QOL CogniFve funcfon

5 Prognosis: Survival by RTOG RPA Class Class Class I <65, KPS >70 Controlled 1 No extracranial dz Class II Everyone else Class III KPS < 70 Survival 7.1m 4.2m 2.3m RPA=recursive parffoning analysis Gaspar L et al, Int J Radiat Oncol Biol Phys, 2000

6 Factors AffecFng Survival in Women with Brain Metastases from Breast Cancer SUBTYPE AGE RACE *OS = Time from Original Breast Cancer Diagnosis to Death Carey Anders, ASCO 2010 Abstract #1027

7 Survival remains poor in patients with triple negative breast cancer and brain metastases. Study Time Period # Pts. Median survival Dawood months Lin months Eichler months Nam months Carey 2010 (abstr #1027) Niwinska 2010 (abstr #1029) months months Survival dominated by extracranial progression

8 Survival may be improving in patients with HER-2+ breast cancer and brain metastases. Study Time Period # Pts Median survival Tham ~3 months Bendell months Gori months Stemmler months Eichler months Melisko months ~50% of paients (in some series) die of CNS progression

9 As cancer therapy improves, our treatments will change: What if the field changes? If breast cancer survival doubles, does that change need for whole brain radiafon? Yes brain is sanctuary site need more aggressive brain therapy No if pafents live longer, side effects will be more evident

10 How do we treat brain metastases?

11 Strategies for Brain Metastases Followed By Surgery Radiosurgery Whole Brain Radia5on ObservaFon Surgery X X X Radiosurgery 4 X 5 Whole Brain RadiaFon 6 7 X Systemic Therapy

12 Disease Extent Dictates Choices Solitary met Oligometastasis Mul5ple metastases

13 When to Operate? Significant mass effect Tumor, edema, blood Unknown diagnosis At presentafon Following radiafon therapy Recurrence Posterior fossa?

14 Improved Survival Following Surgery and RadiaFon or RadiaFon Alone for Single Brain Metastases Median Survival (wks.) P<0.01 Patchell, NEJM, 1990

15 Does Whole Brain RadiaFon Work?

16 PostoperaFve Radiotherapy for the Treatment of Single Brain Metastases: Results P <.001 WBRT No WBRT Patients, % P < P =.003 P < Overall Recurrence Recurrence at Original Site Recurrence at Other Sites Death From Neurologic Causes 1. Patchell RA, et al. JAMA. 1998;.280:

17 Post surgical Radiotherapy for Brain Metastasis: ProspecFve Trial Survival (not significant) radiafon 48 weeks observafon 43 weeks FuncFonal Independence (not significant) radiafon 37 weeks observafon 35 weeks Patchell, JAMA 280:1527, 1998

18 What is cognifve effect of WBRT?

19

20 Chang abstract

21 Randomized 58 PaFents 28 SRS + WBRT 30 SRS alone CogniFve funcfon Chang Lancet Oncology 10:

22 Probability of NeurocogniFve Decline at 4 months aner SRS or SRS/WBRT SRS alone had longer survival (15 m vs. 6 m), more recurrences(27% vs. 73%), worse local control (67% vs. 100%) SRS + WBRT associated with greater risk of learning and memory decline at 4 months then SRS alone. Recommended SRS and close observafon Chang Lancet Oncology 10:

23

24 RTOG 0214 A Sun et al: JCO 29:279, 2011

25 PCI for NSCLC: CogniFve FuncFon A Sun et al: JCO 29:279, 2011

26 PCI for NSCLC: Randomized Trial No differences in Overall survival Disease free survival QOL, ADL Differences in Memory/recall at 1 year (HVLT, immediate and delayed) MMSE, HVLT (immediate and delayed) at 3 months Developing Brain Metastasis ( 8% PCI vs. 18% observafon) A Sun et al: JCO 29:279, 2011

27

28 What do we know about using WBRT It prevents recurrence It doesn t yet prolong survival There are (potenfal) cognifve implicafons Could augmented local therapy be an alternafve in appropriate cases?

29 Use of Local BCNU Wafers in PaFents with Brain Metastases

30 Ewend et. al., Neurosurgery, 1998

31

32 Phase I II Trial of Surgery, BCNU Polymer Wafers, and XRT for Treatment of Brain Mets Single arm, 6 insftufons 25 pafents Brain metastasis pafent appropriate for surgery of single lesion Endpoints Recurrence paserns, survival, toxicity, QOL

33 6 centers; 25 pafents; 52% lung primary

34

35 Recurrence Rates following Surgery/ BCNU Wafers/WBRT Site Number Histology Surgical Bed 0/25 (0%) none In brain, distant to surgery 4/25 (16%) Lung (2) Breast (2) Cauda equina 1/25 (4%) Melanoma MulFple spinal lesions, intradural 1/25 (4%) Yolk sac tumor

36 CombinaFon of surgery, local BCNU and WBRT has very low local recurrence rate. What are the outcomes with surgery and local BCNU alone, especially cognifvely?

37 Effects of Surgery with BCNU Wafer Placement on NeurocogniFve FuncFon in PaFents with One to Three Brain Metastases Ewend MG, Meyers CA, Silva E, Booth Jones M, Jain S, and Brem S Presented at ASCO, May 2011

38

39 PaFent Demographics 59 pafents received BCNU wafers placed 5 excluded for pathology, protocol violafons Pathology 39% NSCLC, 28% melanoma, 13% breast cancer 55.6% had addifonal metastases in other organs Single brain lesion 87%, 2 3 lesions 13% RPA Class 1 36%, RPA Class 2 64%

40 NeurocogniFve TesFng Performed

41 Hopkins Verbal Learning Test: Immediate and Delayed Recall, RecogniFon

42 Controlled Oral Word AssociaFon (COWA) and Trail making test B

43 Local recurrence 14/50 pts.

44 Study Conclusions NeurocogniFve funcfon improved following surgery + BCNU wafer placement Well tolerated Local Recurrence rate (14/50) midway between Surgery + XRT 10% Surgery alone 46%* Compared with Patchell, JAMA, 1998

45 Treatment of Brain Metastases: Conclusions Brain Mets not one disease Histology and subtypes maser Each treatment has a role Whole brain radiafon is effecfve but not a free shot Individualizing therapy is the next challenge Surgical therapy with local therapy can improve cognifve outcomes at one year

46 Treatment of Brain Metastases: Personalizing therapy Conclusions WBRT for those at high risk for early disseminated recurrence Local therapy only for those with localized disease and good long term prognosis How do we figure out at the beginning who is who?

47 QuesFons

48